Cerity Partners LLC boosted its holdings in Amyris, Inc. (NASDAQ:AMRS – Get Rating) by 38.2% in the second quarter, HoldingsChannel reports. The institutional investor owned 33,579 shares of the biotechnology company’s stock after purchasing an additional 9,279 shares during the quarter. Cerity Partners LLC’s holdings in Amyris were worth $63,000 at the end of the most recent reporting period.
A number of other institutional investors have also bought and sold shares of the business. Teacher Retirement System of Texas increased its stake in Amyris by 10.9% in the 1st quarter. Teacher Retirement System of Texas now owns 35,431 shares of the biotechnology company’s stock worth $154,000 after buying an additional 3,471 shares in the last quarter. Lazard Asset Management LLC grew its position in shares of Amyris by 7.9% during the first quarter. Lazard Asset Management LLC now owns 112,422 shares of the biotechnology company’s stock valued at $490,000 after purchasing an additional 8,200 shares in the last quarter. Prospera Financial Services Inc purchased a new position in shares of Amyris during the first quarter valued at about $39,000. Moors & Cabot Inc. grew its position in shares of Amyris by 19.1% during the first quarter. Moors & Cabot Inc. now owns 62,250 shares of the biotechnology company’s stock valued at $271,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Pinnacle Wealth Management Advisory Group LLC purchased a new position in shares of Amyris during the first quarter valued at about $44,000. Hedge funds and other institutional investors own 43.08% of the company’s stock.
Wall Street Analyst Weigh In
Several research analysts recently commented on AMRS shares. JPMorgan Chase & Co. lowered Amyris from an “overweight” rating to a “neutral” rating in a research report on Thursday, November 10th. Oppenheimer lowered Amyris from an “outperform” rating to a “market perform” rating in a research report on Wednesday, November 9th. Cowen dropped their price target on Amyris from $13.00 to $6.00 in a research report on Thursday, November 10th. Roth Capital lowered Amyris from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 10th. Finally, Cowen dropped their price target on Amyris from $13.00 to $6.00 in a research report on Thursday, November 10th. One investment analyst has rated the stock with a sell rating and four have given a hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $5.33.
Amyris Stock Performance
Amyris stock opened at $1.94 on Thursday. The company has a 50 day moving average price of $2.70 and a 200-day moving average price of $2.52. Amyris, Inc. has a fifty-two week low of $1.44 and a fifty-two week high of $6.98. The company has a market capitalization of $630.86 million, a PE ratio of -1.11 and a beta of 1.22.
Amyris, Inc, a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets.
- Get a free copy of the StockNews.com research report on Amyris (AMRS)
- Is the 60/40 Portfolio Mix Still in Vogue?
- Microsoft Shares: Is it Time to Back Up the Truck?
- Three CBD Stocks to Dominate a Budding Industry
- Institutional Support for Analog Devices Remains High
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.